Evidence map›Paper›PMID 39003671›Full record

ArticleJournal of nephrology2025

Phenotypic quantification of Nphs1-deficient mice.

Ronen Schneider, Bshara Mansour, Caroline M Kolvenbach, Florian Buerger, Daanya Salmanullah, Katharina Lemberg, Lea M Merz, Nils D Mertens, Ken Saida, Kirollos Yousef and 9 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Ronen Schneider *Division of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Bshara Mansour *Division of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Caroline M Kolvenbach *Division of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Florian BuergerDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Daanya SalmanullahDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Katharina LembergDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Lea M MerzDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Nils D MertensDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Ken SaidaDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Kirollos YousefDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Gijs A C FrankenDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Aaron BaoDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Seyoung YuDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Selina HölzelDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Camille Nicolas-FrankDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Andrew SteinsapirDeerfield Discovery and Development, Deerfield Management Company, L.P. (Series C), New York, USA.
Kevin A GoncalvesDeerfield Discovery and Development, Deerfield Management Company, L.P. (Series C), New York, USA.
Shirlee ShrilDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA.
Friedhelm HildebrandtDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, USA. friedhelm.hildebrandt@childrens.harvard.edu.

Funding

Integrating large scale genomics and functional studies to accelerate FSGS/NS discoveryRC2DK122397 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HILDEBRANDT, FRIEDHELM, POLLAK, MARTIN R. · 2020 to 2024
$7.4M
RESEARCH TRAINING IN PEDIATRIC NEPHROLOGYT32DK007726 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI BRISCOE, DAVID M. · 1994 to 2023
$5.9M
Identification and function of new genes causing childhood nephrotic syndromeR01DK076683 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HILDEBRANDT, FRIEDHELM · 2007 to 2021
$5.3M
ASN Foundation for Kidney Research 404527522NIDDK NIH HHS 3T32DK007726-38S1NIDDK NIH HHS 5T32-DK007726-37NIDDK NIH HHS R01 DK076683NIDDK NIH HHS RC-2-DK1222397NIDDK NIH HHS RC2 DK122397NIDDK NIH HHS T32 DK007726NIDDK NIH HHS T32-DK007726
6 · The paper itself

Abstract

backgroundSteroid-resistant nephrotic syndrome (SRNS) is the second most frequent cause of chronic kidney disease in children and young adults. The most severe form of steroid-resistant nephrotic syndrome is congenital nephrotic syndrome Finnish type (CNSF), caused by biallelic loss-of-function variants in NPHS1, encoding nephrin. Since each of the 68 monogenic causes of steroid-resistant nephrotic syndrome represents a rare cause of the disease, tailoring therapeutic interventions to multiple molecular targets remains challenging, suggesting gene replacement therapy (GRT) as a viable alternative. To set the ground for a gene replacement study in vivo, we established rigorous, quantifiable, and reproducible phenotypic assessment of a conditional Nphs1 knockout mouse model.

methodsBy breeding a floxed Nphs1

resultsWe observed a median survival to postnatal day P5 in nephrin-deficient mice, whereas heterozygous control mice and wild type (WT) control group showed 90% and 100% survival, respectively (at P50 days). Light microscopy analysis showed a significantly higher number of renal-tubular microcysts per kidney section in nephrin-deficient mice compared to the control groups (P < 0.0022). Transmission electron microscopy demonstrated reduced foot process (FP) density in nephrin-deficient mice compared to controls (P < 0.0001). Additionally, proteinuria quantitation using urine albumin-to-creatinine ratio (UACR) was significantly higher in nephrin-deficient mice compared to controls.

conclusionsThis study represents the first comprehensive description of the kidney phenotype in a nephrin-deficient mouse model, laying the foundation for future gene replacement therapy endeavors.

Indexed as

Membrane ProteinsNephrotic SyndromeAlbuminuriaAnimalsDisease Models, AnimalKidneyMiceMice, Inbred C57BLMice, KnockoutPhenotypePodocytesMembrane ProteinsnephrinCongenital nephrotic syndromeGene replacement therapyNephrin-deficient mouse model

Identifiers

PMID39003671
PMCPMC11772050

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.